{
    "clinical_study": {
        "@rank": "100858", 
        "arm_group": [
            {
                "arm_group_label": "Patients with severe neuropathy", 
                "description": "Patients with severe neuropathy after treatment with paclitaxel.  Blood samples and patient questionnaires will be collected."
            }, 
            {
                "arm_group_label": "Patients without neuropathy", 
                "description": "Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect clinical data, blood samples, and self reported\n      symptoms from patients that experience unusually severe neuropathy after treatment with\n      paclitaxel.  This data will be used to develop predictive markers for neuropathy. Blood\n      samples will be used to create induced pluripotent stem (iPS) cells and eventually\n      artificial nerve cells to be used to study neuropathy in the lab."
        }, 
        "brief_title": "Assessment of Paclitaxel-Induced Neuropathy", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer,", 
            "Breast Cancer,", 
            "Ovarian Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Ovarian Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (Severe Toxicity Group):\n\n          -  Diagnosis of cancer (including, but not limited to, breast and ovarian cancer)\n\n          -  Females aged 18 and older\n\n          -  History of grade 3 or higher peripheral neurotoxicity, any neuromotor, neurocortical,\n             or neurocerebellar toxicity, myalgias or arthralgias refractory to non-steroidal\n             anti-inflammatory drugs and steroids, ong-term persistence (> 6 months) of grade 2 or\n             higher peripheral neuropathy, or other unusually severe neurotoxicity approved for\n             inclusion in study by Principal Investigator after completion of paclitaxel\n             chemotherapy regimen or history of peripheral neuropathy that required treatment with\n             narcotics or grade 2 or higher peripheral neuropathy after only 1 to 2 doses of\n             paclitaxel.\n\n        Inclusion Criteria (Control Group):\n\n          -  History of no neurotoxicity (grade 0) after completion of a standard\n             paclitaxel-containing chemotherapy regimen\n\n          -  Females age 18 and older\n\n          -  Matched to a specified subject with neurotoxicity based on age (within 10 years),\n             tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity\n\n        Exclusion Criteria :\n\n          -  Treatment with other severely neurotoxic chemotherapy (i.e. cisplatin) prior to or\n             concomitantly with paclitaxel. Carboplatin therapy is allowed.\n\n          -  Presence of peripheral neuropathy prior to paclitaxel therapy\n\n          -  Poorly controlled or insulin-dependent diabetes or other condition likely to\n             predispose to neurotoxicity (alcoholism, Charcot-Marie-Tooth disease)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients treated with paclitaxel"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953159", 
            "org_study_id": "IRB13-0775"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Patients with severe neuropathy", 
                    "Patients without neuropathy"
                ], 
                "intervention_name": "Blood Collection", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Patients with severe neuropathy", 
                    "Patients without neuropathy"
                ], 
                "intervention_name": "Patient Questionnaires", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "kkoetter@medicine.bsd.uchicago.edu", 
                "last_name": "Kimberly Koetter, RN", 
                "phone": "773-702-1912"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Gini Fleming, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be assessed for neuropathy symptoms and predictive markers at the time of enrollment.", 
            "measure": "Validation of polygenic risk score", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}